医学
甘油三酯
胆固醇
疾病
动脉粥样硬化性心血管疾病
载脂蛋白B
生物信息学
脂蛋白
内科学
内分泌学
生物
作者
Robert S. Rosenson,Aleesha Shaik,Wenliang Song
标识
DOI:10.1016/j.jacc.2021.08.051
摘要
Emerging evidence suggests that elevated concentrations of triglyceride-rich lipoprotein remnants (TRLs) derived from hepatic and intestinal sources contribute to the risk of atherosclerotic cardiovascular events. Natural selection studies support a causal role for elevated concentrations of remnant cholesterol and the pathways contributing to perturbations in metabolic pathways regulating TRLs with an increased risk of atherosclerotic cardiovascular disease events. New therapies targeting select catalytic pathways in TRL metabolism reduce atherosclerosis in experimental models, and concentrations of TRLs in patients with a vast range of triglyceride levels. Clinical trials with inhibitors of angiopoietin-like 3 protein and apolipoprotein C-III will be required to provide further guidance on the potential contribution of these emerging therapies in the paradigm of cardiovascular risk management in patients with elevated remnant cholesterol.
科研通智能强力驱动
Strongly Powered by AbleSci AI